Ads
related to: docetaxel and carboplatin breast cancer survival rate 20 years later book- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Nurses Station
Explore Resources Made For Nurses
To Learn About A mTNBC Treatment.
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Oncology Co-Pay Program
Downloadable Resources Available
For Your Patients And Practice
- Resources
Access Tools & Resources Available
To Help You Learn About A Treatment
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Ad
related to: docetaxel and carboplatin breast cancer survival rate 20 years later book